From Wikipedia, the free encyclopedia
Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV (AIDS), and Hepatitis C. The company develops antiretroviral drugs for the treatment of AIDS.
[edit] History
In 1994, Rudi Pauwels (Rega Institute for Medical Research) founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joined Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium)[1].
Tibotec licensed TMC120, an NNRTI, to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.
[edit] References
- ^ Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature, 1990, 343, 470-474. doi:10.1038/343470a0
- ^ Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27
[edit] See also
[edit] External links
